Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers

Darryl Claude De Vivo, MD

Spinal Muscular Atrophy (SMA) Center
CUIMC/Neurological Institute of New York
710 West 168th Street, Room 201
New York, New York, United States

Dr. Darryl C. De Vivo, M.D., is the Sidney Carter Professor of Neurology, Professor of Pediatrics, and Director Emeritus (1979-2000) of the Child Neurology Service at Columbia University Irving Medical Center in New York City. Currently, he continues to fulfill his duties as Founding Director, Colleen Giblin Research Laboratories; Director, Pediatric Neuromuscular Disease Center, Co-Director of the Center for Motor Neuron Biology and Diseases (MNC), and Associate Chairman (Neurology) for Pediatric Neurosciences. He has published more than 450 original articles and reviews, lectures extensively in the U.S. and abroad, serves on several editorial boards and advisory committees, and is the Former Associate Editor for Rudolph’s Textbook of Pediatrics. Dr. De Vivo is the Current Editor of “Neuromuscular disorders in Infancy, Childhood and Adolescence: A Clinician’s Approach”, recognized as the standard reference in the field. Dr. De Vivo receives funding from the NIH, DOD, SMA Foundation, MDA, Colleen Giblin Foundation, Milestones for Children and the Will Foundation. He serves as the Director for the PNCR Clinical Trials Network for SMA.

Research Interests: Genetically-determined metabolic diseases that affect the developing brain and neuromuscular system. Specific disorders include Glut1 Deficiency, Mitochondrial Diseases, Epilepsy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA) and other Pediatric Neuromuscular Diseases.

Representative Publications:

Nusinersen Treatment in Adults With Spinal Muscular Atrophy

Ethical Perspectives on Treatment Options With Spinal Muscular Atrophy Patients

Longitudinal Natural History of Type I Spinal Muscular Atrophy: A Critical Review

Treatment of Infantile-Onset Spinal Muscular Atrophy With Nusinersen: Final Report of A Phase 2, Open-Label, Multicentre, Dose-Escalation Study

Related Content